Market: NASD |
Currency: USD
Address: Three Bala Plaza East
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
📈 Larimar Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$19.30
-
Upside/Downside from Analyst Target:
393.61%
-
Broker Call:
21
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-11-06
-
EPS Estimate:
-0.43
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Larimar Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2025-11-06 (estimated upcoming) | - |
| 2025-08-14 | -0.41 |
| 2025-04-30 | -0.46 |
| 2025-03-24 | -0.45 |
| 2024-10-30 | -0.24 |
| 2024-08-07 | -0.34 |
| 2024-05-09 | -0.27 |
| 2024-03-14 | -0.29 |
| 2023-11-14 | -0.21 |
| 2023-08-10 | -0.19 |
| 2023-05-15 | -0.15 |
| 2023-03-14 | -0.21 |
| 2022-11-10 | -0.37 |
| 2022-08-11 | -0.47 |
| 2022-05-12 | -0.49 |
| 2022-03-25 | -0.5 |
| 2021-11-12 | -0.92 |
| 2021-08-12 | -0.79 |
| 2021-05-10 | -0.76 |
| 2021-03-04 | -0.89 |
📰 Related News & Research
No related articles found for "larimar therapeutics".
